Showing 2291-2300 of 2656 results for "".
- Tilak Healthcare Launches US Pilot for OdySight Medical Vision Monitoring Apphttps://modernod.com/news/tilak-healthcare-launches-us-pilot-for-odysight-medical-vision-monitoring-app/2479202/Tilak Healthcare is launching a pilot program in the US with Novartis for OdySight, Tilak’s first clinically tested mobile app for patient remote vision monitoring. The program is the first to launch under an international collaboration announced in 2020 between Tilak Healthcare and
- Zeiss Celebrates 175th Anniversary in 2021https://modernod.com/news/zeiss-celebrates-175th-anniversary-in-2021/2479194/Zeiss’ success story began 175 years ago, in a small workshop. On November 17, 1846, young mechanic Carl Zeiss opened his workshop for precision mechanics and optics in Jena, thus laying the foundation for what would become today’s global technology player Zeiss. Zeiss went on to join
- PharmAbcine Announces Nonclinical Data of PMC-403 for Vessel-Related Diseases at ARVOhttps://modernod.com/news/pharmabcine-announces-nonclinical-data-of-pmc-403-for-vessel-related-diseases-at-arvo/2479187/PharmAbcine announced that the company presented an e-poster featuring nonclinical data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting on May 5th. PMC-403 is the company’s novel agonistic ant
- Palatin Announces Two Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meetinghttps://modernod.com/news/palatin-announces-two-presentations-at-the-2021-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting/2479093/Palatin Technologies announced two presentations of the company’s melanocortin platform, including PL9643 in dry eye disease, at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, being held virtually May 1-7, 2021. The
- Neurophth Announces IND Approval in China for Leber Hereditary Optic Neuropathy Gene Therapyhttps://modernod.com/news/neurophth-announces-ind-approval-in-china-for-leber-hereditary-optic-neuropathy-gene-therapy/2479055/Neurophth Biotechnology announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved the company’s investigational new drug (IND) application of NR082 (recombinant adeno-associated virus serotype 2 carrying ND4 gene; rAAV2-ND
- Johnson & Johnson Takes Charge of Emergent COVID-19 Vaccine Manufacturing Sitehttps://modernod.com/news/johnson-johnson-takes-charge-of-emergent-covid-19-vaccine-manufacturing-site/2479052/The US Department of Health & Human Services (HHS) has put Johnson & Johnson in charge of the Emergent BioSolutions’ Bayview facility in Baltimore, which ruined around 15 million doses of its COVID-19 vaccine Ad26.COV2.S. Johnson & Johnson said it was “assuming full
- Infectious Disease Researcher Appointed Inaugural Chief Scientific Officer at Mass Eye and Earhttps://modernod.com/news/infectious-disease-researcher-appointed-inaugural-chief-scientific-officer-at-mass-eye-and-ear/2479047/Michael S. Gilmore, PhD, a microbiologist who has led infectious disease efforts at leading research institutions, has been appointed the first Chief Scientific Officer at Mass Eye and Ear. Dr. Gilmore will assume the role on May 1, 2021. He has served as Director of the Infectious Disease
- Johnson & Johnson Begins Testing COVID-19 Vaccine in Adolescentshttps://modernod.com/news/johnson-johnson-begins-testing-covid-19-vaccine-in-adolescents/2479045/Johnson & Johnson announced that it has begun vaccinating adolescent participants in an ongoing phase 2a trial of its COVID-19 vaccine candidate Ad26.COV2.S. The study, which got under way last September, was initially designed to evaluate single- and two-dose regimens of the vaccine in healt
- Surface Ophthalmics Announces Preeya K. Gupta, MD, as Chief Medical Advisorhttps://modernod.com/news/surface-ophthalmics-announces-preeya-k-gupta-md-as-chief-medical-advisor/2479032/Surface Ophthalmics announced the appointment of Preeya K. Gupta, MD, as Chief Medical Advisor (CMA). Dr. Gupta will consult with Surface Ophthalmics leaders and lend her expertise, particularly in dry eye disease, to help guide Surface’s three clinical progra
- Pfizer, Moderna COVID-19 Vaccines Show High Efficacy in First US Real-World Studyhttps://modernod.com/news/pfizer-moderna-covid-19-vaccines-show-high-efficacy-in-first-us-real-world-study/2479028/New data released Monday from a US Centers for Disease Control and Prevention (CDC) study of vaccinated health care workers show that mRNA-based coronavirus vaccines by Pfizer and Moderna were 80% effective at preventing infections after one dose, with efficacy climbing to 90% 2 weeks after the s